Pharmaceutical

MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Oct 20, 2024 - 04:00
MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
Read the original article

Tags:

Previous Article

Intercept’s liver disease drug Ocaliva faces FDA approval delay

Next Article

Avadel wins FDA approval for narcolepsy drug Lumryz in children

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Parenteral Solutions in Contract Manufacturing for the Pharmaceutical Industry 

Parenteral Solutions in Contract Manufacturing for the ...

Oct 16, 2024

The ‘Hispanic Paradox’ intrigues a new generation of researchers determined to unravel it

The ‘Hispanic Paradox’ intrigues a new generation of re...

Sep 14, 2023

STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion

STAT+: Merck, Daiichi Sankyo to partner on targeted che...

Oct 20, 2023